thumbnail image
broken image
broken image

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
    • PanCanSeek
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
      • PanCanSeek
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
broken image
broken image

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
    • PanCanSeek
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
      • PanCanSeek
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
broken image
  • SeekInCareTM

    The first-in-class blood-based pan-cancer early detection service

    broken image

    broken image

    When cancer is detected at the early stage, treatment is more effective and survival drastically improves. Yet ~50% of cancers are still only detected at an advanced stage.

    SeekInCareTM is a CE-marked blood-based multi-omics pan-cancer screening test designed to identify cancer at its curable stage, enabling timely intervention to improve clinical outcomes.

    Pan-cancer

    Non-invasive

    Early detection

    Cancer localization

  • Highlights

    • Utilizing AI-powered multi-omics platform to detect cancer signals through a blood test.
    • By analyzing cell-free DNA (cfDNA) via shallow whole-genome sequencing (sWGS), it identifies genomic abnormalities (copy number aberration, fragment size, end motif, and oncogenic virus) and integrates 7 protein tumor markers (PTMs).
    • Through machine learning, a cancer risk score (CRS) for early cancer screening is generated and the tissue of origin (TOO) is predicted when cancer signals are detected.

    broken image
  • Indicated subjects

    broken image

    Adults aged 50+

    Family history of cancer

    Persistent unexplained symptoms

    Chronic inflammatory diseases

    Long-term exposure to cancer-causing environments

    Unhealthy lifestyle

  • Specifications

    ◉ Sample requirement: 8ml peripheral blood

    ◉ Result readout: Cancer Risk Score (CRS) + Tissue Of Origin (TOO)

    ◉ Turnaround time (TAT): 10 working days

  • How it works

    broken image

    Customer order

    Customers can place orders through SeekIn official website or local agents

    broken image

    Blood-draw

    8 ml venous peripheral blood collected in cell-free DNA streck tube and can be stably stored at room temperature for 5 days

    broken image

    Testing

    Detection by Roche cobas e411 instrument + next generation sequencing (NGS) platform

    broken image

    Reporting

    The test results will be ready in about 10 workdays after your blood draw arrived at central lab

  • Please review the instructions to gain a better understanding of SeekInCareTM and assess whether it meets your needs.

    Download the Instructions

Navigation

Technology   

SeekInCare

SeeInCure

SeekInClarity

OncoSeek

Research

Contact Us

10320 Camino Santa Fe, Suite G

San Diego, CA 92121

United States

info@seekincancer.com

© 2024 SeekIn Inc.

All Rights Reserved.

Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Learn More